Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.41 |
| ▸ | HTR2C | P28335 | 7/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29914530 | 0.81 | PDE10A (0.38) | HTR2AHTR2CNPY5RPIK3CDPIK3R1 | |
| SCHEMBL24681279 | 0.81 | PDE10A (0.38) | HTR2AHTR2CNPY5RPIK3CDPIK3R1 | |
| SCHEMBL29914526 | 0.81 | PDE10A (0.38) | HTR2AHTR2CNPY5RPIK3CDPIK3R1 | |
| SCHEMBL24680787 | 0.81 | PDE10A (0.38) | HTR2AHTR2CNPY5RPIK3CDPIK3R1 | |
| SCHEMBL24681006 | 0.80 | NPY5R (0.43) | HTR2AHTR2CNPY5RPIK3CDPIK3R1 | |
| SCHEMBL29914608 | 0.80 | NPY5R (0.43) | HTR2AHTR2CNPY5RPIK3CDPIK3R1 | |
| SCHEMBL29914569 | 0.80 | NPY5R (0.43) | HTR2AHTR2CNPY5RPIK3CDPIK3R1 | |
| SCHEMBL24681623 | 0.80 | NPY5R (0.43) | HTR2AHTR2CNPY5RPIK3CDPIK3R1 | |
| SCHEMBL25966656 | 0.77 | NPY5R (0.36) | HTR2AHTR2CNPY5RPIK3CDPIK3R1 | |
| SCHEMBL13733091 | 0.76 | MEN1 (0.56) | HTR2AHTR2CNPY5RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| EP-4223754-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | AKT2, MTOR, AKT1 | HTR2A 3995/4885HTR2C 3480/4885NPY5R 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.